Table 2.
The values of pharmacological variables obtained from isolated aortic ring studies after 4 weeks of treatment with vehicle or resveratrol
| Phenylephrine | Acetylcholine | |||
|---|---|---|---|---|
| Emax | EC50 | Emax | IC50 | |
| DM2-C-Veh | 100.0±0.0 | -6.76±0.08 | 87.5±3.2 | -7.23±0.13 |
| DM2-Veh | 153.7±26.8* | -7.04±0.09* | 66.7±1.9* | -6.63±0.26* |
| Sham-Veh | 100.0±0.0 | -6.77±0.10 | 87.0±1.5 | -7.13±0.13 |
| HTN-Veh | 173.8±18.2* | -7.37±0.08* | 70.5±2.6* | -6.69±0.28* |
| DM2+HTN-Veh | 165.1±16.0* | -7.29±0.10* | 49.8±1.7* | -6.15±0.37* |
| DM2+HTN-Res5 | 103.6±9.3Δ | -6.10±0.08Δ | 83.8±1.7Δ | -7.07±0.16Δ |
| DM2+HTN-Res10 | 105.5±13.4Δ | -6.91±0.12Δ | 86.7±2.0Δ | -7.16±0.21Δ |
| DM2+HTN-Res20 | 101.4±8.8Δ | -6.70±0.15Δ | 87.5±3.2Δ | -7.3±0.12Δ |
DMC-V: Diabetic control group receiving vehicle; Sham-V: Sham-operated receiving vehicle; DM-V: Diabetic receiving vehicle; HTN-V: Hypertensive receiving vehicle; DM+HTN-V: Diabetic hypertensive receiving vehicle; DM+HTN-R5: Diabetic hypertensive receiving 5 mg/kg/day resveratrol; DM+HTN-R10: Diabetic hypertensive receiving 10 mg/kg/day resveratrol; DM+HTN-R20: Diabetic hypertensive receiving 20 mg/kg/day resveratrol; Emax: Maximal response; EC50: Effective concentration 50; IC50: Inhibitory concentration 50; EC50 and IC50 are presented as antilog of the concentrations; Data are mean±SEM and n=8-10 each; *Significant difference (P<0.05) with DMC-V or Sham-V; ∆Significant difference (P<0.05) with DM+HTN-V